Zevaquenabant , also known as MRI-1867, is a cannabinoid 1 (CB1) receptor antagonist. MRI-1867 is a hybrid molecule that acts both as an inverse agonist of peripheral cannabinoid receptor 1 (CB1) and as an inhibitor of inducible nitric oxide synthase (iNOS). MRI-1867 was initially shown to exhibit anti-fibrotic activity in mouse models of liver fibrosis and it has subsequently been demonstrated to reduce signs of inflammation, fibrosis, oxidative stress and overall renal injury in a mouse model of obesity-induced chronic kidney disease. The therapeutic effect of MRI-1867 is two-fold; it both reduces fibrotic progression and is able to attenuate established fibrosis. Activities at both of its molecular targets are involved in mediating its in vivo efficacy.
MedKoo Cat#: 465972
Name: Zevaquenabant
CAS#: 1998760-00-1
Chemical Formula: C25H21ClF3N5O2S
Exact Mass: 547.1057
Molecular Weight: 547.98
Elemental Analysis: C, 54.80; H, 3.86; Cl, 6.47; F, 10.40; N, 12.78; O, 5.84; S, 5.85
The following data is based on the product molecular weight 547.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
